Crossmark

Targeting <scp>TGF</scp> βR2‐mutant tumors exposes vulnerabilities to stromal <scp>TGF</scp> β blockade in pancreatic cancer

Crossref DOI link: https://doi.org/10.15252/emmm.201910515

Published Online: 2019-10-14

Published Print: 2019-11-07

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Huang, Huocong https://orcid.org/0000-0002-6345-4566
Zhang, Yuqing https://orcid.org/0000-0003-0740-5310
Gallegos, Valerie

Sorrelle, Noah

Zaid, Mohamed Medhat

Toombs, Jason

Du, Wenting

Wright, Steven

Hagopian, Moriah

Wang, Zhaoning

Hosein, Abdel Nasser

Sathe, Adwait Amod

Xing, Chao

Koay, Eugene J

Driscoll, Kyla E

Brekken, Rolf A https://orcid.org/0000-0003-2704-2377
Funding

Funding for this research was provided by:

Eli Lilly and Company (SRA5200886401)

National Institutes of Health (CA192381)

National Institutes of Health (CA210181)

American Heart Association (19PRE34380436)
License Information

Version of Record valid from 2019-10-14
More Information

Publication History

Received: 2019-02-25

Accepted: 2019-09-17

Published: 2019-10-14